

019664-000400US  
March 3, 2000

DIALOG(R) File 351:DERWENT WPI  
(c) 2000 Derwent Info Ltd. All rts. reserv.

008117031

WPI Acc No: 90-004032/199001

XRAM Acc No: C90-001738

XRFX Acc No: N90-003087

Immuno-potentiator for fortified antigen and immunisation procedure -  
composed of cellulose net-like particles of nitrocellulose, for  
inoculation of animals

Patent Assignee: RIKAGAKU KENKYUSHO (RIKA )

Number of Countries: 001 Number of Patents: 002

Patent Family:

Patent No	Kind	Date	Applicat No	Kind	Date	Main IPC	Week
JP 1287032	A	19891117	JP 88114441	A	19880511		199001 B
JP 95116057	B2	19951213	JP 88114441	A	19880511	A61K-039/39	199603

Priority Applications (No Type Date): JP 88114441 A 19880511

Patent Details:

Patent	Kind	Lan	Pg	Filing Notes	Application	Patent
JP 1287032	A		6			
JP 95116057	B2		5	Based on		JP 1287032

Abstract (Basic): JP 1287032 A

Immunopotentiator is composed of cellulose net-like particles.  
Cellulose material is nitrocellulose. Fortified antigen is composed of  
the immunopotentiator and antigen absorbed onto the carrier. The animal  
is inoculated with the fortified antigen for immunization and antibody  
prodn.

USE/ADVANTAGE - The immunopotentiator is used to increase  
immunogenicity and activate immunoreaction. The fortified antigen is  
used as vaccine or for prodn. of monoclonal antibody and various  
antibodies. Monoclonal antibody can be prepd. less expensively and  
vaccine can be prepd. against the virus with very low immunogenicity.

Title Terms: IMMUNO; POTENTIATE; FORTIFIED; ANTIGEN; IMMUNE; PROCEDURE;  
COMPOSE; CELLULOSE; NET; PARTICLE; NITROCELLULOSE; INOCULATE; ANIMAL

Derwent Class: A96; B04; D16; S03

International Patent Class (Main): A61K-039/39

International Patent Class (Additional): A61K-031/72; A61K-039/385;

C12P-021/00; G01N-033/53

File Segment: CPI; EPI

Manual Codes (CPI/A-N): A03-A03; A12-V; A12-V01; B02-V02; B04-B04C1;  
B04-C02A; B12-A01; B12-C09; B12-M11D; D05-H07

Manual Codes (EPI/S-X): S03-E14H4

Plasdoc Codes (KS): 0231 1974 1976 2541 3272 2766 2767

Polymer Fragment Codes (PF):

\*001\* 014 04- 065 231 239 252 393 525 53& 611 623 624 645

Chemical Fragment Codes (M1):

\*01\* K0 K7 K710 M280 M320 M421 M423 M781 M903 P210 P220 P434 Q233 V270  
V280 V712

\*02\* M423 M720 M903 N131 N133 N136 Q233 V600 V611

Derwent Registry Numbers: 1861-U

PA 3054999 v1

019664-000400US  
March 3, 2000

DIALOG(R)File 347:JAPIO  
(c) 2000 JPO & JAPIO. All rts. reserv.

02989432  
ADJUVANT, REINFORCED ANTIGEN AND IMMUNIZATION

PUB. NO.: 01 -287032 [JP 1287032 A]  
PUBLISHED: November 17, 1989 (19891117)  
INVENTOR(s): MURAKAMI YASUFUMI  
SAIJO MASAFUMI  
ONO TADAO  
IGAWA YOJI  
APPLICANT(s): RIKAGAKU KENKYUSHO [000679] (A Japanese Company or  
Corporation), JP (Japan)  
APPL. NO.: 63-114441 [JP 88114441]  
FILED: May 11, 1988 (19880511)  
INTL CLASS: [4] A61K-031/735; A61K-031/715; A61K-039/385; A61K-039/39;  
C12P-021/00; G01N-033/531  
JAPIO CLASS: 14.4 (ORGANIC CHEMISTRY -- Medicine); 14.5 (ORGANIC CHEMISTRY  
-- Microorganism Industry); 46.2 (INSTRUMENTATION -- Testing)  
JAPIO KEYWORD: R014 (MICROFILTERS)  
JOURNAL: Section: C, Section No. 685, Vol. 14, No. 63, Pg. 75,  
February 06, 1990 (19900206)

ABSTRACT

PURPOSE: To obtain an adjuvant to reinforce immunogenicity and to activate immunological reactions artificially carried out in organisms, comprising network structure particles of cellulosic material.

CONSTITUTION: An adjuvant comprising network structure particles of cellulosic material (e.g., nitrocellulose, cellulose phosphate or CMC), preferably particles having 50-200.mu.m, especially 100-200.mu.m diameter and 0.1-0.6.mu.m mesh size of net. The particles, for example, are prepared by finely cutting membrane filters comprising nitrocellulose as a raw material and grinding into a powdery state. Immunization of animal using an extremely small amount of antigen or an antigen having low immunogenicity is made possible by preparing a reinforced antigen comprising a carrier consisting of the adjuvant and an antigen adsorbed on the carrier. Only synthesis of the aimed specific antibody can be introduced without introducing synthesis of nonspecific antibody.

PA 3055000 v1